Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

Sponsor
Tanabe Pharma Corporation
Study ID
NCT03436693
Phase
PHASE3
Status
Completed

Conditions

  • Diabetic Nephropathy

Eligibility Criteria

Sex
ALL
Age
30 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Canagliflozin — DRUG
    Canagliflozin 100mg orally once daily
  • Placebo — DRUG
    Placebo orally once daily

Study Details

The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo

Key Dates

Start date
Feb 15, 2018
Status verified
Dec 2025
Primary completion
Jan 21, 2021
Completion
Jan 21, 2021

Study Design

Enrollment
308 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Canagliflozin 100mg
  • Placebo Comparator: Placebo

Primary Outcome Measure

Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104 [ Time Frame: Week 104 ]

Related Studies